61 related articles for article (PubMed ID: 29463233)
1. Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial.
Fong Y; Halloran ME; Park JK; Marks F; Clemens JD; Chao DL
BMC Infect Dis; 2018 Feb; 18(1):84. PubMed ID: 29463233
[TBL] [Abstract][Full Text] [Related]
2. Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016.
Ferreras E; Matapo B; Chizema-Kawesha E; Chewe O; Mzyece H; Blake A; Moonde L; Zulu G; Poncin M; Sinyange N; Kasese-Chanda N; Phiri C; Malama K; Mukonka V; Cohuet S; Uzzeni F; Ciglenecki I; Danovaro-Holliday MC; Luquero FJ; Pezzoli L
PLoS One; 2019; 14(8):e0219040. PubMed ID: 31469853
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up.
Sévère K; Rouzier V; Anglade SB; Bertil C; Joseph P; Deroncelay A; Mabou MM; Wright PF; Guillaume FD; Pape JW
Am J Trop Med Hyg; 2016 May; 94(5):1136-42. PubMed ID: 26928838
[TBL] [Abstract][Full Text] [Related]
4. Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study.
Mukonka VM; Sialubanje C; Matapo BB; Chewe O; Ngomah AM; Ngosa W; Hamoonga R; Sinyange N; Mzyece H; Mazyanga L; Bakyaita N; Kapata N
BMJ Open; 2023 Oct; 13(10):e070796. PubMed ID: 37798024
[TBL] [Abstract][Full Text] [Related]
5. Do Oral Cholera Vaccine and Water, Sanitation, and Hygiene Combine to Provide Greater Protection Against Cholera? Results From a Cluster-Randomized Trial of Oral Cholera Vaccine in Kolkata, India.
Im J; Islam MT; Ahmmed F; Kim DR; Tadesse BT; Kang S; Khanam F; Chowdhury F; Ahmed T; Firoj MG; Aziz AB; Hoque M; Jeon HJ; Kanungo S; Dutta S; Zaman K; Khan AI; Marks F; Kim JH; Qadri F; Clemens JD
Open Forum Infect Dis; 2024 Jan; 11(1):ofad701. PubMed ID: 38274552
[TBL] [Abstract][Full Text] [Related]
6. Early use of oral cholera vaccines as a prime control measure during outbreaks: Necessary but not sufficient.
El Bushra HE; Haroun AAA; Dauod Altaf M; Gardiwal H; Muhammad Raja A; Alkhidir MA
Vaccine; 2024 Apr; 42(12):3033-3038. PubMed ID: 38594122
[TBL] [Abstract][Full Text] [Related]
7. Methods for the estimation of direct and indirect vaccination effects by combining data from individual- and cluster-randomized trials.
Wang R; Cen M; Huang Y; Qian G; Dean NE; Ellenberg SS; Fleming TR; Lu W; Longini IM
Stat Med; 2024 Apr; 43(8):1627-1639. PubMed ID: 38348581
[TBL] [Abstract][Full Text] [Related]
8. Development of a Scorecard to Monitor Progress toward National Cholera Elimination: Its Application in Uganda.
Bwire G; Sack DA; Lunkuse SM; Ongole F; Ngwa MC; Namanya DB; Nsungwa J; Aceng Ocero JR; Mwebesa HG; Muruta A; Nakinsige A; Kisakye A; Kalyebi P; Kemirembe J; Makumbi I; Kagirita A; Ampeire I; Mutegeki D; Matseketse D; Debes AK; Orach CG
Am J Trop Med Hyg; 2023 May; 108(5):954-962. PubMed ID: 37037429
[TBL] [Abstract][Full Text] [Related]
9. Human Challenge Studies for Cholera.
Cohen MB
Curr Top Microbiol Immunol; 2022 Apr; ():. PubMed ID: 35377003
[TBL] [Abstract][Full Text] [Related]
10. Potential re-emergence of cholera in Brazil.
Martins-Filho PR; Alves Dos Santos C
Lancet Reg Health Am; 2024 Jun; 34():100767. PubMed ID: 38779654
[No Abstract] [Full Text] [Related]
11. A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults.
Keech CA; Morrison R; Anderson P; Tate A; Flores J; Goldblatt D; Briles D; Hural J; Malley R; Alderson MR
Pediatr Infect Dis J; 2020 Apr; 39(4):345-351. PubMed ID: 31895881
[TBL] [Abstract][Full Text] [Related]
12. Oral killed cholera vaccines for preventing cholera.
Saif-Ur-Rahman KM; Mamun R; Hasan M; Meiring JE; Khan MA
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD014573. PubMed ID: 38197546
[TBL] [Abstract][Full Text] [Related]
13. Competing Heterogeneities in Vaccine Effectiveness Estimation.
Nikas A; Ahmed H; Zarnitsyna VI
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631880
[TBL] [Abstract][Full Text] [Related]
14. Competing Heterogeneities in Vaccine Effectiveness Estimation.
Nikas A; Ahmed H; Zarnitsyna VI
ArXiv; 2023 May; ():. PubMed ID: 37205263
[TBL] [Abstract][Full Text] [Related]
15. An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon.
Ateudjieu J; Sack DA; Nafack SS; Xiao S; Tchio-Nighie KH; Tchokomeni H; Bita'a LB; Nyibio PN; Guenou E; Mondung KM; Dieumo FFK; Ngome RM; Murt KN; Ram M; Ali M; Debes AK
Am J Trop Med Hyg; 2022 Nov; 107(5):974-983. PubMed ID: 36395746
[TBL] [Abstract][Full Text] [Related]
16. Estimating Waning of Vaccine Effectiveness: A Simulation Study.
Nikas A; Ahmed H; Zarnitsyna VI
Clin Infect Dis; 2023 Feb; 76(3):479-486. PubMed ID: 36056892
[TBL] [Abstract][Full Text] [Related]
17. Mathematical Modeling of Endemic Cholera Transmission.
Chao DL
J Infect Dis; 2021 Dec; 224(12 Suppl 2):S738-S741. PubMed ID: 34550373
[TBL] [Abstract][Full Text] [Related]
18. Durability of protection after 5 doses of acellular pertussis vaccine among 5-9 year old children in King County, Washington.
Rane MS; Rohani P; Halloran ME
Vaccine; 2021 Oct; 39(41):6144-6150. PubMed ID: 34493409
[TBL] [Abstract][Full Text] [Related]
19. Insights into the gastrointestinal tract microbiomes of Indian population.
Senapati T; Kothidar A; Banerjee SK; DAS B
J Biosci; 2019 Oct; 44(5):. PubMed ID: 31719222
[TBL] [Abstract][Full Text] [Related]
20. The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis.
Khan AI; Levin A; Chao DL; DeRoeck D; Dimitrov DT; Khan JAM; Islam MS; Ali M; Islam MT; Sarker AR; Clemens JD; Qadri F
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006652. PubMed ID: 30300420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
